Nanobiotix

Nanobiotix S.A. is a clinical-stage biotechnology company focused on developing first-in-class product candidates that leverage its proprietary nanotechnology to transform cancer treatment by enhancing the efficacy of radiotherapy. Their lead product candidate, NBTXR3, is an aqueous suspension of functionalized crystalline hafnium oxide nanoparticles designed for direct injection into malignant tumors prior to standard radiotherapy. When exposed to ionizing radiation, NBTXR3 amplifies the local tumor-killing effect of the radiation and may also stimulate the body's immune response against cancer. NBTXR3 aims to enhance the overall efficacy of radiotherapy without causing additional side effects to surrounding healthy tissues.